ResearcherUniversitätsmedizin GöttingenActive in the last 2 years
Adi Danieli‐Mackay
Matched on ORCID iD 0000-0001-7337-3797; OpenAlex author ID A5005091141. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 4
- Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2026.117649↗
- Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-08362-w↗
- A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. Co-author DOI 10.1093/nargab/lqae057↗
- TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Co-author DOI 10.1038/s43018-021-00258-w↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Gabriela Salinas · 3 shared papers, 2024–2026 · strength 0.64
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649↗
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w↗
- Paper A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. DOI 10.1093/nargab/lqae057↗
- Argyris Papantonis · 3 shared papers, 2021–2026 · strength 0.52
- Paper Targeting addiction to HMGB2-driven transcriptional programs in pancreatic cancer. DOI 10.1016/j.celrep.2026.117649↗
- Paper A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. DOI 10.1093/nargab/lqae057↗
- Paper TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cance… DOI 10.1038/s43018-021-00258-w↗
- Elisabeth Heßmann · 3 shared papers, 2021–2025 · strength 0.52
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w↗
- Paper A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. DOI 10.1093/nargab/lqae057↗
- Paper TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cance… DOI 10.1038/s43018-021-00258-w↗
- Matthias Dobbelstein · 2 shared papers, 2025–2026 · strength 0.43
- Emre Taylan Duman · 2 shared papers, 2024–2026 · strength 0.43
- Shiv K. Singh · 2 shared papers, 2021–2026 · strength 0.31
- Lukas Klein · 2 shared papers, 2021–2026 · strength 0.31
- Volker Ellenrieder · 2 shared papers, 2021–2024 · strength 0.31
- Paper A single-cell strategy for the identification of intronic variants related to mis-splicing in pancreatic cancer. DOI 10.1093/nargab/lqae057↗
- Paper TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cance… DOI 10.1038/s43018-021-00258-w↗
- Tiago De Oliveira · 1 shared paper, 2026 · strength 0.22
- Lena‐Christin Conradi · 1 shared paper, 2026 · strength 0.22
- Constanza Tapia Contreras · 1 shared paper, 2025 · strength 0.21
- Carolin Schneider · 1 shared paper, 2025 · strength 0.21
- Maj-Britt Paulsohn · 1 shared paper, 2025 · strength 0.21
- Günter Schneider · 1 shared paper, 2025 · strength 0.21
- Elisa Espinet · 1 shared paper, 2021 · strength 0.10
- Uday Kishore · 1 shared paper, 2021 · strength 0.10
- Andreas Trumpp · 1 shared paper, 2021 · strength 0.10
- Laura Urbach · 1 shared paper, 2021 · strength 0.10
- Stephan A. Hahn · 1 shared paper, 2021 · strength 0.10
- Mengyu Tu · 1 shared paper, 2021 · strength 0.10
- Albrecht Neeße · 1 shared paper, 2021 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.